Additional consideration upon achievement of certain development and commercial milestones.

No definition available.

Name:	iron_AdditionalConsiderationUponAchievementOfCertainDevelopmentAndCommercialMilestones
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Certain commercial milestone payments for certain licensed antibody product net sales achievements.

+ References

No definition available.

+ Details

Name:	iron_CertainCommercialMilestonePaymentsForCertainLicensedAntibodyProductNetSalesAchievements
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Certain development and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	iron_Certaindevelopmentandregulatorymilestonepayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contingent Payments.

+ References

No definition available.

+ Details

Name:	iron_ContingentPayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Future milestone payment.

+ References

No definition available.

+ Details

Name:	iron_FutureMilestonePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Future payments upon commercialization.

+ References

No definition available.

+ Details

Name:	iron_FuturePaymentsUponCommercialization
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Future payments upon sales-based milestones.

+ References

No definition available.

+ Details

Name:	iron_FuturePaymentsUponSalesBasedMilestones
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Future payments upon the achievement of certain development.

+ References

No definition available.

+ Details

Name:	iron_FuturePaymentsUponTheAchievementOfCertainDevelopment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Non refundable upfront fee.

+ References

No definition available.

+ Details

Name:	iron_NonRefundableUpfrontFee
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront non-refundable payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontNonRefundablePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontPayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_AbbvieDeutschlandGmbhCoKgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_MabwellTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Development and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended				3 Months Ended
	Oct. 31, 2023	May 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Mar. 31, 2024	Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense					$ 23,704,000	$ 20,180,000
License and Stock Purchase Agreement \| AbbVie
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment					0
Non refundable upfront fee				$ 600,000
License and Stock Purchase Agreement \| AbbVie \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future payments upon the achievement of certain development				18,000,000
Future payments upon commercialization				45,000,000
Future payments upon sales based milestones				$ 87,500,000
License Agreement \| Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment					0
Non-refundable upfront payment		$ 4,000,000	$ 500,000
Additional consideration upon achievement of certain development and commercial milestones			120,000,000
License Agreement \| Mabwell
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment	$ 5,000,000
Research and development expense					0	10,000,000
Upfront payment						$ 10,000,000
License Agreement \| Mabwell \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Certain development and regulatory milestone payments					127,500,000
Certain commercial milestone payments for certain licensed antibody product net sales achievements					$ 275,000,000
Development and Regulatory Milestone First Indication \| License Agreement \| Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments			50,000,000
Development and Regulatory Milestone Second Indication \| License Agreement \| Roche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments			$ 35,000,000